Mission Cancer + Blood opens new clinic in Waukee
WAUKEE, Iowa — Cancer care is expanding to the west of the metro. On Monday, Mission Cancer + Blood opened a new clinic in Waukee.
It's located at 2565 SE Encompass Drive and provides 32 more treatment chairs for chemotherapy and immunotherapy, as well as on-site labs.
With Iowa having one of the fastest growing cancer rates in the country, doctors say it's important to serve patients in their communities.
'For anyone who's been treated in our downtown offices, the wait can be long,' Dr. Seema Harichand, hematologist and oncologist at Mission, said. 'So having the ability to sort of spread that out over different offices also makes it easier and less inconvenient for people. Cancer care entails a lot of visits, a lot of treatment, and the more convenient we can make it for patients, the easier their journey will be.'
Mr. Worldwide and legendary rock band to play Grandstand at Iowa State Fair
Earlier this year, Mission officially became part of University of Iowa Health Care. Dr. Harichand says the partnership will allow patients more access to new cancer treatments.
'We hope that the University of Iowa will help us expand our clinical trial portfolio,' Dr. Harichand said, 'not only locally but also help us improve access for patients who need to go and be seen at the University to be able to get care more easily and maybe quickly.'
Mission has more than 20 other community locations across Iowa.
To learn more, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Another way mom's health in pregnancy could impact baby long-term
There's an increased risk that women with high blood pressure while they're pregnant will have children who have seizures, according to a new study led by researchers at University of Iowa Health Care. The study, which included other researchers from Stanford University and in Taiwan, was published in the Journal of Clinical Investigation. In a news release, the university said the findings suggest inflammation in the brain could play a role in the relationship between gestational hypertension and seizure risk, offering a potential target to prevent seizures in children whose mom had high blood pressure while they were in the womb. Just over 1 in 6 pregnant women have gestational hypertension, which has been associated with various complications for both the mothers and the babies they carry. The researchers say this is the first large-scale study showing a link between high blood pressure and increased seizure risk in offspring. Johns Hopkins University, which was not involved in the study, reports that seizures in children likely result from disturbances in electrical activity in the brain. They can range in severity from brief staring spells to active jerking motion to loss of consciousness. The Centers for Disease Control and Prevention emphasizes that high blood pressure in pregnancy is treatable — and can often be prevented. 'We examined large national clinical databases as well as databases at the University of Iowa and Stanford University, and we even have international collaborations with database analysis from our collaborators in Taiwan,' Dr. Alex Bassuk, professor and head of pediatrics at the University of Iowa, who was the study's senior author, said in a written statement. 'This was a real team effort spanning several countries and institutions, and involved multiple departments at the University of Iowa, including pediatrics, obstetrics and gynecology and psychology.' The study used data from the Epic Cosmos dataset, with more than 246 million patient records taken from clinics and hospitals in the United States and Lebanon. Then they used animal models to provide added support to their findings. The researchers found that children born to mothers who had high blood pressure while pregnant had significantly higher rates of seizures compared to those whose mothers had normal blood pressure. They also looked at the association using data from 'smaller, richly annotated cohorts' at the University of Iowa, Stanford and the addition of data from Taiwan to back up the findings. In an effort to understand the link, the researchers developed two mouse models of gestational hypertension. Both confirmed that exposure to gestational high blood pressure in the womb increased both seizure sensitivity and death from seizures among offspring. The mouse model, too, identified brain inflammation as significant in the disease process, highlighting sex-specific differences in which male offspring were more vulnerable to seizures. Dr. Vinit Mahajan, a professor of ophthalmology at Stanford and a study co-author, said they were able to reduce the seizures in the mice by using anti-inflammatory drugs, 'based on what we learned from the model.' The researchers hope that their findings will lead to further study and different approaches to treating gestational hypertension and reducing children's seizures. 'The connection between high blood pressure in pregnant moms and seizures in children from these pregnancies had been postulated before, but never examined on a large scale, and never modeled in an animal. With these new mouse models and this new connection between gestational hypertension and seizures, we can now perhaps come up with new childhood anti-seizure therapies,' says Baojian Xue, who has a doctorate and is a senior research scientist in pediatrics at the University of Iowa. He is first author on the study, which was funded in part by grants from the National Institutes of Health, The Tross Family Epilepsy Fund, and Research to Prevent Blindness. The CDC said it's important to ask your health care provider about medications — both prescription and over-the-counter — that are safe to take while you're pregnant. The public health giant also emphasizes the need for early and regular prenatal care. It says to go to every appointment. Pregnant women should not start or stop a medication without checking with their health care provider, per CDC. Women who are pregnant should track their blood pressure at home and let their doctor know if it's higher than usual or if there are troubling symptoms. Often, a doctor or insurance company can help arrange for a home monitor. Finally, the CDC says to eat a nutritious diet and maintain a healthy weight.
Yahoo
a day ago
- Yahoo
Pregnant mothers' high blood pressure linked to this increased risk in children
Pregnant mothers experiencing high blood pressure may have to worry about another potential health risk to their children, researchers warned on Monday. The condition, also known as gestational hypertension, has previously been linked to premature births and stillbirths that are tied to a decrease in blood flow through the placenta. Now, researchers at University of Iowa Health Care have found it is also associated with an increased risk for seizure in kids. "The connection between high blood pressure in pregnant moms and seizures in children from these pregnancies had been postulated before, but never examined on a large scale, and never modeled in an animal,' Dr. Baojian Xue, a senior research scientist in pediatrics at the university, commented on the research. 'With these new mouse models and this new connection between gestational hypertension and seizures, we can now perhaps come up with new childhood anti-seizure therapies," he wrote. Xue was the first author of the National Institutes of Health-funded study, which was published in the Journal of Clinical Investigation. To reach these conclusions, they utilized clinical databases and studies in lab mice, including the records of more than 246 million patients from across the U.S. The study found that children born to mothers with high blood pressure during their pregnancy had significantly higher rates of seizures compared to those with normal blood pressure. In mice, testing confirmed that exposure to gestational hypertension in the womb increased seizure sensitivity and death due to seizures. Of their subjects, male offspring showed greater vulnerability to the medical condition. They also found that brain inflammation played a 'significant role' in the process of disease, saying it may play such a role in human children. Gestational hypertension impacts nearly 16 percent of American pregnancies. Mothers are also at a higher risk of seizures, stroke, temporary kidney failure, and liver and blood clotting problems, according to the Cleveland Clinic. Most people with high blood pressure will deliver healthy babies when the condition is caught early in pregnancy. However, the more severe the condition is, the more at risk mothers are for serious complications, the clinic notes. That can include preeclampsia, when high blood pressure develops after 20 weeks of pregnancy. Eclampsia occurs when a pregnant woman has seizures due to untreated or under-treated preeclampsia. But this study – the first large-scale evidence connecting gestational hypertension to heightened seizure risk in offspring – may offer new pathways for further research. The impact of brain inflammation could be targeted to prevent seizures in children exposed to gestational hypertension. Notably, this research was released the same day as another study from Columbia University that found low levels of arsenic in drinking water were also linked to preterm birth and lower birthweight. "This study is unique because you have an association drawn from analyses of large clinical databases, but then we go on to prove the association with animal models,' Dr. Vinit Mahajan, professor of ophthalmology at Stanford University and a co-author on the study, explained. 'We were even able to reduce seizures in mice offspring with anti-inflammatory drugs based on what we learned from the model.'
Yahoo
7 days ago
- Yahoo
World Precision Instruments and SynVivo Launch Next-Generation Multiplexed TEER-on-a-Chip Platform for Real-Time Organ-on-a-Chip Cell Monitoring
SARASOTA, Fla. and HUNTSVILLE, Ala., June 11, 2025 /PRNewswire/ -- World Precision Instruments (WPI), a global leader in transepithelial electrical resistance (TEER) instrumentation, and SynVivo Inc., a pioneer in Organ-on-a-Chip (OOC) technology, today announced the commercial launch of a next-generation multiplexed TEER-on-a-Chip platform—a breakthrough solution enabling real-time, high-throughput measurement of barrier integrity in advanced Organ-on-a-Chip models. The co-developed platform integrates WPI's gold-standard EVOM™ measurement technology with SynVivo's SynTEER™ multiplexed OOC models with embedded electrodes, providing researchers with a seamless solution for performing TEER measurements directly within microfluidic chips. Initially validated on SynVivo's advanced SynBBB™ Blood-Brain Barrier model, this is the first in a planned series of Organ-on-a-Chip platforms powered by the new EVOM-Chip™ system from WPI. With electrodes embedded directly into SynVivo's SynTEER™ multiplexed OOC models researchers can now perform real-time TEER measurements across multiple channels—enabling continuous barrier monitoring, streamlined workflows, and improved reproducibility. The EVOM-Chip™ system allows for hands-free, simultaneous data collection, and remains fully compatible with live-cell imaging and physiologically relevant flow conditions. "This collaboration represents a major advancement in functional barrier modeling," said Gwen Fewell, President & CEO of SynVivo Inc. "Integrating TEER measurement directly into our chip enhances data fidelity, reduces variability, and streamlines experimental workflows—key to enabling more predictive, standardized and scalable in vitro models. By combining our vascularized OOC technology with WPI's industry-leading TEER measurement expertise, we're delivering a powerful solution for researchers tackling complex questions in CNS drug development, inflammation, and drug discovery." WPI's EVOM™ family of TEER instrumentation has set the standard for barrier function assessment for over 30 years. SynVivo's SynTEER™ platform builds on this legacy with pre-integrated, precisely aligned electrodes designed to optimize TEER signal fidelity across a range of Organ-on-a-Chip applications. As the OOC market rapidly grows, it continues to face challenges around standardization and automation, both of which are essential for mainstream adoption in pharmaceutical research. "A critical gap has been the ability to perform on-chip, non-destructive sensing—particularly TEER measurements—a need shared by the majority of OOC platforms but rarely implemented successfully or in a multiplex fashion," explains Mark Rutledge, CEO of WPI. "With EVOM™ Chip, researchers can monitor their OOC platforms from cell seeding through barrier formation, as well as before, during and after drug treatment, to get accurate and reproducible readouts, without affecting the health or well-being of the cells." The system's initial application on the SynBBB™ Blood-Brain Barrier platform has demonstrated a strong correlation between electrical resistance and functional barrier properties, supporting its use in CNS drug development, inflammation studies, and neurovascular research. See It Live at MPS World Summit – Brussels, June 10–13, 2025Visit WPI and SynVivo at the MPS World Summit to explore the EVOM-Chip™ and SynTEER-on-a-Chip systems in action and learn how integrated TEER-on-Chip technology can accelerate your research. WPI Booth #131 SynVivo Booth #404 ABOUT WORLD PRECISION INSTRUMENTS For over 55 years, World Precision Instruments (WPI) has been a leading global manufacturer and provider of innovative research equipment and laboratory supplies to the life sciences, pharmaceutical, health care, and industrial markets. Our proven technology supports complex model development, including preclinical models and organ-on-a-chip systems, providing researchers with the tools to identify and validate drugs to understand mechanism of action, dosage, administration, drug-drug interactions, patient-specific reactions, pharmacokinetics, pharmacodynamics, safety and efficacy. Our areas of innovation focus on tissue and cell biology, fluidics, animal physiology and electrophysiology. With an extensive global network and a passion for innovation, WPI provides novel solutions to customers' daily challenges. For more information, visit About SynVivoSynVivo is a pioneering organ-on-chip company developing physiologically relevant tissue models for drug discovery, disease research, and safety testing. Its advanced microfluidic platforms replicate human tissue microenvironments to enhance the predictive accuracy of in vitro testing. SynVivo is committed to bridging the gap between traditional preclinical models and human clinical outcomes, advancing a new standard in predictive, human-relevant drug development. View original content to download multimedia: SOURCE SynVivo and World Precision Instruments Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
